Development of experimental alloxan model of diabetes mellitus
Main Article Content
Background. One of the main causes that lead to the disability of diabetic patients is diabetic retinopathy (DR). The relevance of the problem of DR necessitates the development of optimal experimental models on experimental animals to find effective ways of correcting this pathology. The purpose of our work was to develop an experimental alloxan model of type 1 diabetes mellitus (DM) for the study of DR, which would not result in the lethal outcome of experimental animals under the action of alloxan; histological examination of changes in the tissues of the eyeball in the reproduction of the DM model for the selection of new effective methods for the metabolic treatment of DR in the early stages. Materials and methods. The experiment was carried out on white outbred Wistar rats weighing 180–200 g. The first group consisted of 20 animals that were not subjected to any influence, served as a control; second group — 30 animals, in which DM was modeled by administration of alloxan and fructose. Results. When modeling DR, vessel changes in the form of wall fibrosis, edema of the endothelium and vasospasm were found. There was also a decrease in the amount of pigment granules, dystrophic changes in the cells of the ganglionic layer and a layer of retinal rods and cones, which coincides with the descriptions of damage to the coats of the eyeball in patients with DM. Conclusions. In our studies, we have calculated the optimal dose of alloxan administration, which does not lead to the death of rats (the lethality of rats was absent) and is an effective model not only of DM in general, but also of DR.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our edition uses the copyright terms of Creative Commons for open access journals.
Authors, who are published in this journal, agree with the following terms:
- The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
- Directing the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
- The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
- The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
- The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
- The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
World Health Organization. Diabetes. WHO Newsletter. November 2016 [Electronic resource]. (In Russian). Available from: http://www.who.int/mediacentre/factsheets/fs312/ru/
Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006 Nov;3(11):442. doi: 10.1371/journal.pmed.0030442.
Maslova O.V, Suncov JuI. Epidemiology of diabetes mellitus and microvascular complications. Diabetes mellitus. 2011;3:6-11. (In Russian).
Pan'kiv V.I. Diabetes mellitus: definition, classification, epidemiology, risk factors. Mezhdunarodnyi Endokrinologicheskii Zhurnal. 2013;7(55):95-104. (In Ukrainian). doi: 10.22141/2224-07188.8.131.523.84685.
Bezdetko PA, Gorbachova OV. Epidemiology and frequency of diabetes mellitus and diabetic retinopathy. Mezhdunarodnyi Endokrinologicheskii Zhurnal. 2006;4(6):37-45. (In Ukrainian).
Zelins'ka NB, Horoshaja OO, Starynec’ NA. The frequency of diabetic retinopathy in children and adolescents with diabetes according to screening in the regions of Ukraine. Klinichna endokrynologija ta endokrynna hirurgija. 2005;4(13):27-31. (In Ukrainian).
Semeraro F, Cancarini A, dell’Omo R, et al. Diabetic retinopathy: vascular and inflammatory disease. Journal of Diabetes Research. 2015;3:1–17. doi: 10.1155/2015/582060.
Vergouwe Y, Soedamah-Muthu S, Zgibor J, et al. Progression to microalbuminuria in type 1 diabetes: development and validation of prediction rule. Diabetologia. 2010;53:254-62. doi: 10.1007/s00125-009-1585-3.
Petrovski G, Kaarniranta K, Petrovic D. Oxidative stress, epigenetics, environment, and epidemiology of diabetic retinopathy. Journal of Diabetes Research. 2017;2:1-3. doi: 10.1155/2017/6419357.
Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res. Clin. Pract. 2010;87(1):4-14. doi: 10.1016/j.diabres.2009.10.007.
Nentwich MM, Ulbig MW. Diabetic retinopathy – ocular complications of diabetes mellitus. World J Diabetes. 2015;6(3):489-99. doi: 10.4239/wjd.v6.i3.489.
Ueda K, Nakahara T, Hoshino M, et al. Retinal blood vessels are damaged in rat model of NMDA induced retinal degeneration. Neuroscience Letters. 2010;485(1):55-9. doi: 10.1016/j.neulet.2010.08.061.
Balabolkin MI. The role of glycation of proteins, oxidative stress in the pathogenesis of vascular complications in diabetes mellitus. Sakharnyi diabet.2002;4:8-16. (In Russian).
Verma S, Buchanan MR, Anderson TJ. Endothelial Function Testing as a Biomarker of Vascular Disease. Circulation. 2003;108:2054-9. doi: 10.1161/01.CIR.0000089191.72957.ED.
Bonetti PO, Lerman LO, Lerman A. Endothelial Dysfunction: A Marker of Atherosclerotic Risk. Arterioscler Thromb Vascular Bio. 2003;23:168-75. PMID: 12588755.
Widlansky ME, Gokce N, Keaney JF Jr, Vita JA. The clinical implications of endothelial dysfunction. Journal of the American College of Cardiology. 2003 Oct;42:1149-60. PMID: 14522472.
Chatzigeorgiou A, et al. The use of animal models in the study of diabetes mellitus. In Vivo. 2009;23:245-58. PMID: 19414410.
Pal'chikova NA, Kuznecova NV, Kuz'mynova OI, Seljatyckaya VG. Hormonal and biochemical features of alloxan and streptozotocin-induced models of experimental diabetes. Sibirskij nauchnyj medicinskij zhurnal. 2013;33(6):18-24. (In Russian).
Lenzen S. The mechanisms of alloxan- and streptozotocin-induced diabetes. Diabetologia 2008 Feb;51(2):216-26. doi: 10.1007/s00125-007-0886-7.
Baranov VG, Sokoloverova IM, Gasparjan EG. et al. Eksperimental'nyj saharnyj diabet. Rol' v klinicheskoj diabetologii [Experimental diabetes mellitus. Role in clinical diabetes]. Leningrad: Nauka; 1983. 240 p. (In Russian).
Elsner M, Tiedge M, Guldbakke B, et al. Importance of the GLUT2 glucose transporter for pancreatic beta cell toxicity of alloxan. Diabetologia. 2002 Nov;45(11):1542-9. doi: 10.1007/s00125-002-0955-x.
Evan AP, Mong SA, Connors BA, et al. The effect of alloxan, and alloxan-induced diabetes on the kidney. Anat Rec. 1984;208(1):33-47. doi: 10.1002/ar.1092080105.